Denise A. Yardley, MD, discusses the promise of CDK4&6 inhibitors in estrogen receptor (ER)-positive breast cancer, as well as the potential with immunotherapy agents.
Chelsea LoCascio
Articles by Chelsea LoCascio
Laura J. van’t Veer, PhD, discusses determining more accurate methods of treatment for patients with early- and late-stage breast cancer based on advances in genetic testing, specifically the 70-gene prognostic signature.
Latest Updated Articles
Expert Discusses QoL Concerns With Extended Adjuvant Hormonal Therapy in ER+ Breast CancerPublished: November 3rd 2017 | Updated:
- Expert Discusses Impact of Genetic Testing in Breast Cancer
Published: November 29th 2017 | Updated:
- CDK4&6 Inhibitors Revolutionize Hormone-Positive Breast Cancer Care
Published: December 19th 2017 | Updated: